Cyclophosphamide Dosing Guidelines

Introduction to Cyclophosphamide Regimens

• The American College of Physicians and other medical societies recommend cyclophosphamide dosing varies significantly by indication: for chemotherapy, use 40-50 mg/kg IV divided over 2-5 days or 600 mg/m² every 21 days in combination regimens; for autoimmune diseases, use either oral therapy at 1-3 mg/kg/day (maximum 200 mg/day) or IV pulse therapy at 15 mg/kg (maximum 1500 mg) every 2-4 weeks with mesna protection 1

Chemotherapy Dosing

• The National Comprehensive Cancer Network recommends the AC regimen: Cyclophosphamide 600 mg/m² IV on day 1, cycled every 21 days for 4 cycles 2, 3
• The National Comprehensive Cancer Network recommends the TAC regimen: Cyclophosphamide 500 mg/m² IV on day 1 with doxorubicin and docetaxel, cycled every 21 days for 6 cycles (requires filgrastim support) 2, 3
• The National Comprehensive Cancer Network recommends the TC regimen: Cyclophosphamide 600 mg/m² IV on day 1 with docetaxel, cycled every 21 days for 4 cycles 2, 3
• The National Comprehensive Cancer Network recommends dose-dense AC: Cyclophosphamide 600 mg/m² IV every 14 days for 4 cycles with filgrastim support 2, 3

Autoimmune Disease Dosing

• The British Society for Rheumatology recommends oral daily therapy for adults: 1-3 mg/kg/day (maximum 200 mg/day) with dose adjustments based on white blood cell counts 1
• The British Society for Rheumatology recommends oral daily therapy for pediatric patients: 1.5-3 mg/kg/day 1
• The British Association of Dermatologists defines treatment failure as failure to achieve disease control after 3 months at 2 mg/kg/day 4, 5
• The European League Against Rheumatism recommends intravenous pulse therapy: 15 mg/kg (maximum 1500 mg) initially every 2 weeks, then reducing to every 3 weeks for maximum 6 months 4, 1

Disease-Specific Protocols

• The European Vasculitis Study Group recommends ANCA-Associated Vasculitis treatment: 15 mg/kg IV (maximum 1500 mg) initially every 2 weeks, reducing to every 3 weeks, continued for 3-6 months for remission induction 6, 1
• The British Association of Dermatologists recommends Pemphigus Vulgaris (DCP Regimen) treatment: 500 mg IV cyclophosphamide on day 2 of monthly cycles with dexamethasone 100 mg IV on 3 consecutive days, plus oral cyclophosphamide 50 mg daily between pulses 4, 5

Critical Safety Measures

• The American College of Physicians recommends mesna administration: Required for all patients receiving pulse cyclophosphamide to prevent hemorrhagic cystitis (occurs in 6% without protection) 4, 1
• The National Comprehensive Cancer Network recommends pneumocystis jirovecii prophylaxis: Trimethoprim/sulfamethoxazole 800/160 mg on alternate days or 400/80 mg daily for all patients on cyclophosphamide 1

Dose Modifications

• The European League Against Rheumatism recommends dose reductions for moderate to severe renal impairment 6
• The British Geriatrics Society recommends age-related adjustments: patients 60-70 years, reduce pulse dose by approximately 20%; patients >70 years, reduce pulse dose by approximately 30-50% depending on renal function 6

Major Toxicities to Monitor

• The American Society of Clinical Oncology reports gonadal toxicity: amenorrhea occurs in 20-85% of menstruating women; azoospermia in men 4, 5, 1
• The British Association of Dermatologists reports urinary tract toxicity: hemorrhagic cystitis in 6% without mesna protection 4, 1
• The National Comprehensive Cancer Network reports secondary malignancies with long-term use 1

Cyclophosphamide Dosing for CNS Vasculitis

Dosing Regimens

• The American College of Nephrology recommends an oral daily dose of 2 mg/kg/day (maximum 200 mg/day) for 3-6 months, with age adjustments to 1.5 mg/kg/day for patients 60-70 years and 1.0 mg/kg/day for patients >70 years, as documented in the Kidney International journal 7
• The European League Against Rheumatism suggests an intravenous pulse dose of 15 mg/kg (maximum 1500 mg) at weeks 0, 2, 4, 7, 10, 13, with an extended protocol of additional doses at weeks 16, 19, 21, 24 if disease activity persists, as reported in the Kidney International journal 7
• The Annals of the Rheumatic Diseases journal notes that IV pulse therapy has equivalent efficacy to oral daily dosing but with lower cumulative exposure and reduced long-term toxicity risk 8

Glucocorticoid Co-Administration

• The American College of Rheumatology states that glucocorticoids are mandatory with cyclophosphamide for CNS vasculitis and contribute significantly to early disease control, with an initial therapy of IV methylprednisolone 1000 mg/day for 3-5 days, as recommended in the Arthritis and Rheumatology journal 9
• The European Respiratory Society suggests an oral continuation of prednisone 1 mg/kg/day (maximum 60-80 mg/day) for the first month, as documented in the Annals of the Rheumatic Diseases journal 10 and the Kidney International journal 7
• The British Medical Journal recommends a rapid taper protocol, reducing to 15 mg/day by 12 weeks, then to 5 mg/day by 6 months, as reported in the BMJ journal 11 and the Kidney International journal 7

Critical Safety Measures

• The Infectious Diseases Society of America recommends pneumocystis jirovecii prophylaxis with trimethoprim/sulfamethoxazole 800/160 mg on alternate days or 400/80 mg daily for all patients, as documented in the Annals of the Rheumatic Diseases journal 10 and 8
• The American Urological Association suggests bladder protection with MESNA (2-mercaptoethanesulfonate sodium) with IV pulse cyclophosphamide to prevent hemorrhagic cystitis, as reported in the Annals of the Rheumatic Diseases journal 10 and 8

Maintenance Therapy After Remission

• The European League Against Rheumatism recommends azathioprine 2 mg/kg/day for 18-24 months as a maintenance therapy after achieving remission with cyclophosphamide, as documented in the Annals of the Rheumatic Diseases journal 12

Cumulative Dose Limits

• The American Society of Clinical Oncology notes that limiting total cumulative cyclophosphamide exposure reduces malignancy risk (bladder cancer, myelodysplasia), as reported in the Annals of the Rheumatic Diseases journal 8

CAP Chemotherapy Protocol for Thymoma

Regimen Composition

• The NCCN recommends the standard CAP regimen for thymoma consisting of cisplatin 50 mg/m² IV, doxorubicin 50 mg/m² IV, and cyclophosphamide 500 mg/m² IV administered on day 1 of each cycle, with cycles repeated every 21 days (3 weeks). 13
• Doxorubicin is given at a dose of 50 mg/m² IV on day 1 of each cycle. 14
• Cycle frequency is every 3 weeks (21 days). 15

Administration Details

• All three agents are administered on day 1 of the cycle, with appropriate intravenous hydration before and after cisplatin to mitigate nephrotoxicity. 14
• Response assessment (radiologic and clinical) should be performed after 2–4 cycles to determine whether the tumor remains resectable. 16

Alternative CAP Variant

• An NCCN‑endorsed variant adds oral prednisone 100 mg daily on days 1–5 of each cycle. 13

Clinical Efficacy

• In prospective NCCN‑guided studies, the CAP regimen achieved an objective response rate (ORR) of approximately 50 % in patients with advanced or recurrent thymoma, including three complete responses and twelve partial responses. 17
• In the RYTHMIC prospective database, CAP produced a higher ORR (44 %) compared with non‑CAP systemic therapy (17 %). 18

Safety Monitoring

• Cardiotoxicity is monitored by tracking cumulative doxorubicin exposure, with a recommended upper limit of roughly 450–550 mg/m². 14
• Peripheral neuropathy is assessed through ongoing clinical evaluation throughout treatment. 18

Integration with Multimodal Therapy

• For locally advanced, potentially resectable thymoma (stage III/IVA, Masaoka‑Koga), NCCN guidelines endorse CAP as induction chemotherapy (typically 2–4 cycles), followed by imaging reassessment of resectability. If complete resection is achievable, surgery is performed and postoperative radiotherapy is administered as indicated. 16

Alternatives for Anthracycline Contraindication

• When doxorubicin cannot be used (e.g., pre‑existing cardiac disease or prior cumulative dose), NCCN recommends anthracycline‑free options such as carboplatin combined with paclitaxel. 17

Key Warnings

• The CAP regimen for thymoma is distinct from other CAP regimens used in different malignancies; dosing and schedule are not interchangeable. 15
• During concurrent thoracic radiotherapy, the total heart dose should be limited to ≤30 Gy to protect long‑term cardiac health. 13